April 2018 – First FDA approval for use of Tracer-QC (Press Release).


October 2017 – First order received for Tracer-QC product.

September 2017 – FDA continues funding and collaboration for Year 3 (U01FD005517-03).

June 2017 – Tracer-QC product launched at SNMMI-2017.

January 2017 – NCI awards Trace-Ability the Phase II SBIR Grant for the development of next generation system (2R44CA192499-02).


September 2016 – Based on Year 1 results, FDA approves Year 2 funding and collaboration focused on Tracer-QC validation (U01FD005517-02).

June 2016 – Tracer-QC validation studies start at Zevacor Pharma

February 2016 – NSF awards Trace-Ability the Phase II SBIR Grant for the development of pilot kit production (IIP-1555815).

January 2016 – NSF (IIP‐1446677) and NCI (1R43CA192499-01) Phase I SBIR Grants successfully completed with positive results.


September 2015 – Trace-Ability receives funding from the FDA for an FDA-collaborative project focused on validation of Tracer-QC and its rollout for PET tracer release testing (U01FD005517-01).

June 2015 – Tracer-QC makes its first appearance at a trade show.  More than 100 visitors inquired about the system in 3.5 days at SNMMI-2015 (Society of Nuclear Medicine and Molecular Imaging) in Baltimore MD.

March 2015 – Trace-Ability signs partnership agreement with LabLogic Systems, Ltd. which accelerates product launch and will make Tracer-QC available worldwide through LabLogic’s extensive network.

January 2015 – NSF and NIH award two SBIR grants for the development of Tracer-QC™.